Achieve Life Sciences, Inc.
ACHV Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 27, 2026
$6.93
KIRA · Stoqly’s AI analyst, in plain words
- Achieve Life Sciences, Inc. lost $54.6M in fiscal 2025.
- Free cash flow was −$49.5M in fiscal 2025, — of revenue.
Market cap
$648M
P/E
—
Revenue
—
Net income
−$54.6M
Free cash flow
−$49.5M
Operating margin
—
Achieve Life Sciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$54.6M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Achieve Life Sciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- ACHIEVE LIFE SCIENCES, INC.
- CIK
- 0000949858
Achieve Life Sciences, Inc. · ACHV
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$33.2M | −$42.4M | −$29.8M | −$39.8M | −$54.6M |
| Diluted EPS | −$4.08 | −$4.00 | −$1.50 | −$1.24 | −$1.25 |
| Cash | |||||
| Cash from operations | −$29.4M | −$37.6M | −$24.5M | −$29.8M | −$49.5M |
| Capital expenditure | — | — | $0.0M | — | $0.0M |
| Free cash flow | — | — | −$24.5M | — | −$49.5M |
| Share count change | 198.6% | 30.5% | 87.2% | 61.8% | 35.9% |
| Debt and strength | |||||
| Cash and short-term investments | $43.0M | $24.8M | $15.5M | $34.4M | $36.4M |
| Shareholders' equity | $28.0M | $8.3M | −$1.4M | $20.9M | $21.5M |
| Current ratio | 9.8x | 1.3x | 0.8x | 5.5x | 4.4x |
| Returns and quality | |||||
| Return on equity | −101.5% | −233.0% | −869.9% | −409.5% | −257.7% |
| Return on tangible equity | −130.7% | −723.8% | — | −210.8% | −276.9% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.2M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Achieve Life Sciences, Inc. · ACHV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.93 a share, the company is worth $648M.
Source: SEC EDGAR XBRL filings (CIK 0000949858). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.